International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

Vol. 42 No. 1 December 2023, pp. 44-60

Biomarkers of Neonatal Sepsis

Review

Maged Naser[1], Mohamed M. Nasr[2], and Lamia H. Shehata[3]

[1]Mazahmiya Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of ob/gyn,

[2]King Fahd Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of Surgery,

[3]Care National Hospital, Department of Radiology

Abstract – Neonatal sepsis is a bacterial bloodstream infection predominant to excessive clinical manifestations frequently associated with loss of existence or irreversible long-term deficits. Antibiotics are the drug of choice to address sepsis, no matter age. In neonates, the lack of dependable requirements for a unique prognosis and the supposition that an early antibiotic administration ought to restrict sepsis improvement in youngsters at chance have brought about an applicable antibiotic overuse for each prevention and therapy. the provision of biomarkers of neonatal sepsis that have to alert the physician to an early analysis of neonatal sepsis may additionally want to decorate the quick and long-term outcomes of real sepsis instances and restrict the indiscriminate and deleterious use of preventive antibiotics. The fundamental aim of this assessment is to summarize the crucial outcomes in this regard and to detail the accuracy of currently used biomarkers for the early prognosis of neonatal sepsis. Literature assessment showed that, irrespective of excessive studies, the diagnosis of neonatal sepsis and the behaviour of antibiotic remedy cannot be at current determined on the basis of a single biomarker. Given the significance of the hassle and the want to decrease the abuse of antibiotics, in addition studies are urgently required. but, as a substitute of looking for new biomarkers, it looks less complicated and greater productive to test combinations of or extra of the existing on hand biomarkers. furthermore, research based mostly on omics applied sciences have to be strongly boosted. but, while geared up for new statistics, the use of the clinical ratings prepared through some medical institutions must be counselled. Based totally on maternal risk factors and infant clinical signs, sepsis threat may be calculated, and a big reduction in antibiotic intake may be obtained.

Keywords – Biomarker, Early Onset Sepsis, Late Onset Sepsis, Neonatal Sepsis, Neonatal Infections.

I. INTRODUCTION

Neonatal sepsis is a bacterial bloodstream infection main to extreme clinical manifestations regularly related with death or irreversible long-term deficits. Death can appear in 3–4% and up to 24% of neonates born in industrialized nations [1] and in the developing world [2], respectively. Among survivors, detrimental neurodevelopmental effects at follow-up, along with cerebral palsy, decreased intellectual and psychomotor development, and vision impairment are the most long-term deficits [3].

According to most experts, neonatal sepsis is labelled as early onset sepsis (EOS) if recognized in the first 72 h after beginning or as late onset sepsis (LOS) if recognized after this duration [4]. EOS is basically due to vertical transmission of Escherichia coli and Group B Streptococcus from women with chorioamnionitis, prolonged rupture of membranes, and GBS colonization. LOS is frequently precipitated with the aid of pathogens received nosocomially in neonates at risk due to prematurity, presence of invasive instrumentation, use of parenteral nutrition, and mechanical ventilation [5,6]. Data regarding the epidemiology of neonatal sepsis range drastically in accordance to the standards used to outline the disease [4]. However, it has been calculated that in industrialized countries, incidence of EOS and LOS is no less than 0.3–0.8 cases/1000 live births and about 6 cases/1000

Corresponding Author: Maged Naser

live births, respectively [7,8]. Significantly greater values, up to quite a several dozen/1000 live births, have been calculated for developing countries [9]. Together with the country of birth, a number of different elements have an effect on the hazard of neonatal sepsis development. Among these, birth weight (BW) and gestational age (GA) are two elements that are inversely related with neonatal sepsis occurrence. In very low beginning weight (VLBW) neonates, even in industrialized countries, rates of EOS and LOS increase to 20/1000 and 200/1000, respectively [10]. Similarly, 36.3% of neonates with a GA< 28 weeks have at least one episode of LOS, as in contrast with 29.6%, 17.5%, and 16.5% of these with a GA of 29–32 weeks, 33–36 weeks, and term infants [11].

Diagnosis of neonatal sepsis, in particular of EOS, can be very difficult on the foundation of clinical findings. In adults and in older children, sepsis is described as a life-threatening organ dysfunction brought about via a dysregulated host response to infection. Presence and severity of organ dysfunction is set up the usage of validated scoring systems that identify and quantify abnormalities in accordance to medical findings, laboratory data, or therapeutic measures [12]. Unfortunately, this definition can't be utilized to neonates as numerous studies have proven that whilst the use of standards organized for adults and older children, a great variety of documented neonatal sepsis cases have been now not identified. In a study involving 476 term neonates, the identification of EOS used to be feasible solely in 53% of enrolled infants[13]. A higher variety of sepsis cases are misplaced when preterm neonates are studied [14]. Several elements provide an explanation for why standards used to outline sepsis in adults do now not follow to neonates. Neonates, the increased the prematurity, the greater probable the neonate is to have an immature immune system[15]. This leads to a multiplied threat of infection and to an exclusive inflammatory and medical response to any infectious agent. Moreover, reactions of neonates to harmful stimuli are pretty similar; regardless, they are infectious, metabolic, or traumatic [16]. Early-stage symptoms of sepsis in neonates are refined and non-specific and common to different conditions. Respiratory problems, bradycardia, cyanosis, and temperature instability are described in infants with sepsis however can be found in neonates as an index of negative adaptation to extrauterine life or as signs of a non-infectious disease [17]. Because of this, the definition of sepsis in neonates is nonetheless lacking, and various scientific establishments have advised particular standards for the suitable identification of sepsis in neonates. In most cases, collectively with child conditions, precise parameters which include local epidemiology, GA, and a number of maternal characteristics are regarded to put together a risk calculator that is used to determine which children need treatment [18,19].

Antibiotics are the drug of choice to deal with sepsis, regardless of age. In neonates, the lack of reliable standards for a definite diagnosis and the supposition that early antibiotic administration ought to decrease sepsis development in children at hazard have led to relevant antibiotic overuse for both prevention and remedy [20,21]. Since the starting of the antibiotic era, in most hospitals, all neonates at chance of infection, together with most preterm infants, have been given large spectrum antibiotics, even in the absence of a medical manifestation suggesting infectious disease [22]. Despite this negative, prescriptive attitude have been in part decreased with the aid of the introduction, at least in some hospitals, of particular stewardship programs [23,24], however antibiotic overuse in neonates nonetheless persists and is related with various problems [25,26]. It favours emergence of antimicrobial resistance and promotes dysbiosis, which has been related with the improvement of life-long undesirable health problems, such as obesity, type I diabetes, asthma, autism spectrum disorders, necrotizing enterocolitis, and earlier death [27]. The availability of markers of neonatal sepsis that may address the health practitioner to an early diagnosis of neonatal sepsis may want to enhance the short and long-term effects of true sepsis cases and minimize the indiscriminate and deleterious use of preventive antibiotics. In the last 30 years, quite several tries to become aware of biomarkers of neonatal sepsis have been made. The principal purpose of this review is to summarize the fundamental effects in this regard and to element the accuracy of presently used biomarkers for the early diagnosis of neonatal sepsis.

Table 1. Töllner sepsis scoring system

Score	0	1	2	3
Change in skin colour	Absent		Moderate	Evident
Peripheral circulatory disorder	Absent		Impaired	Evident
Hypotonia	Absent	Moderate	Evident	
Bradycardia	Absent	Present		
Apnea	Absent	Present		
Respiratory distress	Absent	Present		
Hepatomegaly	Absent	>4cm		
GIS finding	Absent	Present		
Leukocyte count	Normal	Leukocytosis		Leukopenia
Left shifting	Absent		Moderate	Evident
Thrombocytopenia	Absent		Present	
Metabolic acidosis	Normal	>7.2	<7.2	

If the total score is below 5, it is normal, between 5-10 it is suspected, and above 10 points, it is considered as definite sepsis.

Table 2. EMA sepsis scoring system

Clinical Findings	Laboratory Findings
Body temperature:	Leukocyte count:
>38.5 ºC or	<4.000/mm3 or >20.000/mm3
<36 ºC and/or temperature irregularities	
Cardiovascular instability:	Immature/total neutrophil ratio:
Bradycardia or tachycardia and/or	≥0.2
rhythm irregularity	
Urine amount <1 ml/kg/hour	
Hypotension	
Impaired peripheral perfusion	
Skin and subcutaneous lesions:	**Platelet Count:**
Petechiae	<100.000/mm3
Sclerema	
Respiratory instability:	CRP >15mg/L (1.5 mg/dL) or
Apnea or	procalcitonin ≥2 ng/mL
Tachypnea or	
Increased oxygen demand or	
Increased need for ventilation support	
Gastrointestinal:	**In blood sugar monitoring (at least twice):**
Nutritional intolerance	Hyperglycemia (>180 mg/dL or 10 mMol/L) or
Insufficient breastfeeding	Hypoglycemia (<45 mg/dL or 2.5 mMol/L)
Abdominal distention	
Non-specific:	**Metabolic acidosis:**
Irritability	Base deficit >10 mEq/L or
Lethargy	Serum lactate >2 mMol/L
Hypotonia	

Positivity in at least two of the clinical categories and at least two of the laboratory categories is considered as clinical sepsis. It can be used up to postnatal 44 weeks.

1. Characteristics of an Ideal Biomarker of Neonatal Sepsis

For a long time, the characteristics of an ideal marker for the early identification of children with EOS or LOS have been exactly described [28]. It has been established that an ideal marker must unexpectedly increase after disease onset and equally minimize as soon as the infection has been cured. It need to have excessive sensitivity (~100%) and specificity (>85%) in the diagnosis of neonatal sepsis, with a high negative predictive value (~100%) and positive predictive value (>85%). Moreover, it ought to supply dependable records on when to begin and when to end antibiotic remedy in order to minimize antibiotic overuse, incorporate the development of bacterial resistance, and keep away from widespread change of intestine microbiota. Maternal, perinatal, or postnatal elements ought to no longer impact its physiologic kinetic. Finally, techniques for marker detection ought to be easy to perform, comparable between different laboratories, require very small amounts of the sample, and be cost effective [28].

2. Biomarkers Presently Used in Clinical Practice

2.1. Hematological Biomarkers

2.1.1. Blood Culture:

As neonatal sepsis is the consequence of a bacterial infection, traditionally, a positive blood culture is regarded the gold standard for the prognosis of this disease. However, blood cultures have a long turnaround time (TAT) and very low sensitivity that make a contribution to inappropriate antibiotic therapy. About 70% of septic neonates have low-colony-count bacteraemia that end result in negative cultures [29]. Moreover, it requires an invasive technique to draw blood. Finally, outcomes are strongly conditioned with the aid of the inoculant volume. The recommended minimal blood extent for the culture in newborn infants is 1 mL, however it has been determined that up to 60% of pattern volumes in medical practice are limited to 0.5 mL, main to a negative test [30]. These findings spotlight that a blood culture is now not appropriate for the prognosis of neonatal sepsis. Important advances can be made the use of molecular methods, such as a polymerase chain response (PCR), real-time PCR, pyro sequencing, and micro fluidic technology [31]. The availability of dependable consequences is extensively accelerated from days to hours. Sensitivity is extensively increased. In a meta-analysis of 23 research evaluating common blood cultures to molecular methods, it was once calculated that the sensitivity and specificity of PCR assays carried out the best with 96% sensitivity and 96% specificity [32]. However, molecular strategies committed to bacterial identification do now not permit for one to recognize the antibiotic susceptibility of the infecting pathogen. Moreover, they require specialised biology laboratories and unique equipment, as well, that are now not handy in many clinic settings, especially in the third world.

2.1.2. White Blood Cell Count, Absolute Neutrophil Count, Immature-to-Total Neutrophil Ratio and Platelet Count:

A high-quality variety of research have evaluated the function of white blood cell count (WBC), absolute neutrophil count (ANC), immature-to-total neutrophil ratio (I/T), and platelet count number as a potential markers of neonatal sepsis [33-39]. These tests are nonetheless broadly used due to the fact they are technically easy and affordable in cost, have a shorter TAT, and do no longer require superior laboratory machineries and well-trained laboratory personnel. Unfortunately, most of the research checking out these biomarkers have serious obstacles inside the design, pattern size, and sepsis case definition that restriction reliability of results. Moreover, the interpretation of learn about outcomes is hampered through the proof that quite a few maternal and neonatal factors, such as maternal blood pressure, gestational age, technique of delivery, sex and age in hours of the child, and, finally, the approach of blood sampling, can extensively regulate all these indices [37]. Similar values have been observed in neonates with sepsis, in wholesome children, and in topics with a specific disease, making differentiation between infected and non-infected infants virtually not possible in most EOS and LOS cases. In a study about examining whole blood counts from 30,000 healthful neonates, which includes 852 infants < 28 weeks gestation, ANC measured between delivery and the stop of the 3rd day of lifes different from 1500/mm3to 41,000/mm3 and from the third day till the tenth day of existence from 1100/mm3 to 15,300/mm3[38]. The evaluation of records gathered in a cohort of 166,092 neonates with suspected EOS and blood cultures published that, even though low WBC count (<100/mm3; and <5000/mm3), low ANC (<100/mm3), and low I/T (<0.20) had been relatively precise due to the fact they have been related with gowing odds of infection (5.38, 6.84, and 7.97, respectively), all these markers had very bad sensitivity [38]. Generally, it was once <20% for all the markers. Only I/T < 20 had a better, even though suboptimal, sensitivity, various from 65.1% to 73.7% in accordance to GA. Moreover, 60% of children with a positive

culture had a WBC count number in the regular range. Similar findings confirming excessive specificity and very low sensitivity of these biomarkers for sepsis identification had been pronounced in a find out about involving neonates with LOS documented with the aid of blood cultures [38]. Some advances can be made by way of deferring determinations till at least 4 h of age in order to limit the interference of perinatal elements or evaluating serial determinations and categorizing the outcomes and intervals, alternatively than dichotomizing them into normal and abnormal ranges. Although repeated blood drawing can't be advocated in neonates, Murphy and Weiner validated that two everyday I/T ratios correlated with a sterile blood subculture and had a most poor predictive fee of 100%, permitting at least to cut out sepsis even if they should now not affirm the diagnosis [39]. Combining these biomarkers with each other or with different biomarkers can enhance results, however usually with first-rate interpretative limits [40]. On the different hand, interpretation for neutrophils and band varieties from stained blood smears is, per se, a limit, as it can drastically range from laboratory to laboratory [41].

2.2. Inflammatory Biomarkers

2.2.1. C-Reactive Protein:

C-reactive protein (CRP) is a pentameric acute-phase protein specifically produced by means of the liver as a response to the insult of a number agents. Together with the WBCs and the differential count, CRP has been for years the most used biomarker to discover neonates with sepsis and nevertheless stays one of the most frequent exams in this regard. CRP manufacturing is influenced by using proinflammatory cytokines like interleukin (IL)-6, IL-1, and tumour necrosis issue α (TNFα) [28]. The principal receptor of CRP is phosphocholine, one of the essential aspects of bacterial membranes. After binding with the receptor, CRP prompts the complement cascade favouring phagocytosis and the expression of proinflammatory mediators [42]. The very best ranges of CRP are observed in serum,.This explains why consequences are conflicting and why, collectively with research displaying sufficient sensitivity and/or specificity, countless research document very bad accuracy of CRP for early sepsis identification. Firm conclusions can't be drawn, even though the delayed upward thrust of CRP as a response to infection appears to endorse that a single dedication of this protein has an unacceptably low sensitivity for events use in medical practice, mainly when EOS is considered. This conclusion is in addition supported via the proof that CRP concentrations are drastically influenced now not solely with the aid of infections, however by means of countless different elements also, making the definition of a dependable cut-off fee very difficult.

CRP spontaneously will increase in the course of the first three days of existence in a top notch variety of wholesome neonates or in babies with non-infective conditions, like a stressful delivery, prolonged labour, meconium aspiration syndrome, delayed transition after birth, prolonged rupture of membranes, haemolysis, intraventricular haemorrhage, or perinatal asphyxias [43]. Perrone et al. confirmed that CRP mean values in healthy children have been substantially greater at 48 h of life (4.10 mg/L) than at 24 (2.30 mg/L) and 12 h (0.80 mg/L), and that children born through vaginal delivery and emergency caesarean section had a CRP greater than in these born by way of elective caesarean segment (3.80 mg/L and 3.60 mg/L vs. 2.10 mg/L) [44]. Moreover, children born to a woman that had received, carried out or now not completed, intrapartum antibiotic prophylaxis had decrease CRP values than these born to untreated women (2.90 mg/L and 3.80 mg/L vs. 4.70 mg/L). Furthermore, gestational age (GA) plays a role in conditioning CRP regular levels. Preterm infants have decrease CRP levels than time period infants with values that had been located to increase via 0.405 mg/L for each and every one week of GA increase. To overcome these limitations, it has been proposed to use CRP with one-of-a-kind cut-off degrees in accordance to GA and mode of delivery [117], and to operate serial determination inside 24–48 h from infection onset in order to evidence CRP progressive increase in neonates developing sepsis [45]. Despite these restrictions as a diagnostic marker of sepsis, CRP can be used to exclude sepsis. Normal CRP values in serial controls within a few days from symptom onset are viewed indicative of the absence of a bacterial infection [46]. Moreover, CRP can be used to display response to antibiotic administration and to determine when antimicrobial remedy can be suspended. Finally, this marker can be used in affiliation with different sepsis markers to enhance the accuracy of the diagnosis of each EOS and LOS. Several studies in which CRP values have been combined with early sensitive markers such as PCT, IL-6, IL-8, and CD64 have proven an increase in sensitivity between 90% and 100% [47].

2.2.2. Procalcitonin:

Procalcitonin (PCT) is a peptide precursor of calcitonin without hormonal activity produced by way of the liver and, at a lower extent, by using monocytes. In healthy humans outside the neonatal period, serum PCT concentration is extraordinarily low (0.01 µg/L). However, after exposure to pro-inflammatory stimuli, particularly of bacterial origin like endotoxins, concentration rises

quickly, within 2 to 4 h, peaks within 6 to 8 h, and stays extended up to 48 h after stimuli are withdrawn [48]. Starting from this evidence, PCT is viewed an early-to-intermediate rising biomarker. Synthesis is stimulated by means of the identical cytokines which stimulate CRP production, such as IL-6, IL-1β, and TNF-α, though PCT can additionally be immediately inspired via bacterial lipopolysaccharides. Contrariwise, PCT is down regulated through interferon-γ, which is contently produced in response to viral infections [49-51]. This explains why PCT is viewed as a top marker of bacterial infection and a measure to differentiate bacterial from viral infections. Unfortunately, as CRP, in healthy neonates, PCT spontaneously will increase after birth, reaches height values at about 24 h of age, and then decreases step by step within 48–72 h, even though with variations in accordance to GA [52,53]. Preterm neonates have an earlier, higher, and longer PCT response than time period neonates, displaying an inverse relationship between GA and the depth of neonatal PCT response. Reference PCT values in accordance to GA and days of life have been organized and used to calculate unique cut-off values for EOS prognosis [54]. However, their use in this regard is appreciably impaired with the aid of the proof that now not solely bacterial infections, however additionally quite a few non-infective perinatal circumstances, such as intraventricular haemorrhage, perinatal asphyxia, respiratory distress, haemodynamic instability, and fetal distress, may also additionally increase serum levels of PCT variations, making closing comparison very hard or completely impossible [55,56]. On the contrary, PCT can provide greater dependable data for LOS diagnosis as, in children with this condition, physiological variations of PCT serum ranges no longer intrude and detected PCT concentrations point out greater exactly the existence of a bacterial infection. Data accrued in each preterm and term neonates have proven Values > 2 µg/L have been these related with the highest sensitivity and specificity, whereas decrease cut-off values have been much less effective in figuring out children with LOS [57]. However, as for CRP, the accuracy of PCT in EOS and LOS diagnosis will increase considerably when serial determinations within a few hours are performed. Persistently low PCT tiers eliminate EOS and LOS. Moreover, in positive cases, normalization of PCT concentrations can be used to figure out the discontinuation of antibiotic remedy [58]. Finally, the combined use of PCT and different laboratory markers can enhance informations [59].

2.2.3. Serum Amyloid A:

Similar to CRP and PCT, serum amyloid A (SAA) is an acute phase reactant. It is synthetized in the liver and, to a decrease extent, in smooth muscle cells, macrophages, adipocytes, and endothelial cells in response to various stimuli, which include infections [60]. Its production happens under IL-1, IL-6, TNF-α, and Gram-negative micro organism lipopolysaccharides (LPBs) stimulation with concentrations that extensively differ in accordance to age [28]. The lowest levels are considered in cord blood whilst the highest levels had been found in aged patients [61]. The kinetic characteristics of SAA appear to recommend that it ought to be a dependable biomarker of neonatal sepsis, as it will increase within a few hours from sepsis onset and returns to baseline degrees after 4 days. Compared with CRP, SAA levels easier and sharper, attain greater levels, and return quicker to normal levels when infection is cured [62]. Moreover, in a study about in which SAA was once in contrast to quite a few different biomarkers of neonatal sepsis, it was once located to be the most favourable and promising marker for prognosis and monitoring of response to cure [63]. The efficacy of SAA for early prognosis of each EOS and LOS used to be proven via most of the study trying out SAA in clinical practice [64,65]. Superiority over CRP used to be said via Arnon et al. [66]. These authors confirmed that serum SAA measured at disorder onset had higher accuracy for predicting EOS than CRP (sensitivity 96% vs. 30%, specificity 95% vs. 98%, tremendous predictive cost 85% vs. 78%, negative predictive value 99% vs. 83%). However, this discovering used to be now not established in the meta-analysis by using Yuan et al. in which 9 studies enrolling 823 preterm and term neonates with EOS and LOS had been evaluated [67]. Pooled sensitivity and specificity of the SAA check for the prognosis of neonatal sepsis at disorder onset had been 84% and 89%, respectively. Only barely lower values have been calculated 8–96 h after the first suspicion of sepsis with a pooled sensitivity of 78% and specificity of 84%. The sensitivity and specificity of CRP had been drastically similar. The heterogeneity of the studied populace and distinction in cut-off values used to outline regular and extraordinary values of each biomarkers can also give an explanation for these differences. On the other hand, it can't be forgotten that SAA, like CRP and PCT, rises up in response to non-infective stimuli, for example, stressful delivery and intraventricular haemorrhage, and that the role of GA in conditioning SAA levels is now not definitively established.

2.2.4. Proadrenomedullin:

Adrenomedullin is a peptide produced by means of heart, adrenal medulla, lungs, kidneys, and vascular endothelium during physiological stress. It regulates the vascular tone, favouring organ perfusion, and exerts a considerable antibacterial and immunomodulatory response [68]. A precursor of noradrenalin, proadrenomedullin (ProADM), has been examined as biomarker of severe bacterial disease in each children and adults. It used to be proven that ProADM sharply will increase rapidly after

infection and is a proper indicator of disease severity and death risk. Data accrued in neonates seem to advocate that ProADM can be used to diagnose EOS and to predict response to antibiotic therapy. In a study learn about enrolling 60 newborns with sepsis tested with wonderful blood cultures and 30 wholesome neonates, pro-ADM serum concentrations had been notably greater (14.39 ± 0.75 nmol/L) in the sepsis group than in controls (3.12 ± 0.23 nmol/L). Sensitivity for the prognosis of sepsis used to be 93.3%, and specificity 86.7% [69]. However, as ProADM serum values are greater in preterm than in term babies, higher prediction of EOS relies upon on the use of exceptional cut-off ranges in accordance to GA (3.9 nmol/L in term neonates and 4.3 nmol/L in preterm babies) [70]. Better consequences have been suggested when ProADM used to be used in mixture with different markers [71].

2.2.5. Other Inflammatory Markers:

Adipokines such as visfatin and resistin, hepcidin, progranulin, stromal cell-derived factor1, endocan, and pentraxin-3 play a function in immune device response and irritation improvement and have been indicated as workable markers of sepsis in neonates [72-76]. However, studies in this regard are very few and similarly records is wished to draw firm conclusions.

2.2.6. Cytokines:

After infecting pathogens are diagnosed by way of toll-like receptors, host immune response is initiated in most cases through the launch of proinflammatory cytokines from macrophages and monocytes [77]. Because of this early involvement in the host immune response to infections, cytokines have been viewed as promising biomarkers of neonatal sepsis, specially in latest years when most issues of cytokine detection in blood samples have been solved [78]. Moreover, as CRP and PCT manufacturing relies upon on cytokine release, it was once idea that the measure of cytokines should provide an in earlier and greater high quality assessment of sepsis improvement in contrast to the historically used biomarkers. Unfortunately, no longer all the predicted advantages have materialized.

A-Interleukin 6:

IL-6 is launched within 2 h after the onset of bacteraemia, peaks at about 6 h, and declines over the following 24 h. Moreover, it can be detected in the blood of neonates 1–2 days earlier than the medical presentation of culture-proven sepsis [79]. Finally, when septic patients get hold of appropriate antibiotic treatment, IL-6 decreases precipitously returned to the baseline non-infectious state within 24 h [80]. These characteristics considerably limit the role of IL-6 as clinically useful biomarkers throughout all EOS and LOS phases, which includes the monitoring of remedy efficacy and duration. Moreover, the practicable use of IL-6 for early identification of infected neonates at hazard of EOS development is hampered by way of the proof that this cytokine is a vital mediator of host response to stress and tissue harm [17] and will increase even in uninfected neonates with hypoxia, fetal distress, prematurity, chorioamnionitis, mechanical ventilation, surfactant therapy, meconium aspiration, and intrauterine growth retardation [81].

Despite cut-off limits for this marker now not being definitively established, the serial measurements of IL-6 or combinations with other specific biomarkers of infection should enhance the diagnostic potential of IL-6. Berka et al. assessed IL-6 at 2 h and at 12–24 h after delivery in very preterm neonates and found that amplify of IL-6 values to > 200 ng/L could diagnose EOS with a sensitivity of 89% and specificity of 77% [82]. The negative predictive value used to be 98%. The same authors in a retrospective case-control find out about recognized values of IL-6 <100 ng/L e CRP < 10 mg/L as correct cut-offs for ruling out LOS at clinical onset [83]. Significantly larger inflammatory response in gram-negative sepsis than in gram-positive sepsis has been demonstrated; Celik et al. discovered a cut-off level of 202 pg/mL for IL-6 differentiated gram-negative from gram-positive sepsis with 68% sensitivity and 58% specificity [89]. It has been found (177) that IL-6 (>400 pg/mL) alone or in aggregate with TNF-α (>32 pg/mL), IL-8 (>200 pg/mL), and granulocyte-colony stimulating thing (>1000 pg/mL) had a hundred percent sensitivity, specificity, poor predictive value, and 38–69% wonderful predictive fee to differentiate gram-negative neonatal sepsis [84].

B-Interleukin-8:

IL-8 has kinetic characteristic very comparable to these of IL-6 and, like this, can increase in newborns regardless of the presence of an infection. It consequently has the identical limitations, specially for the early diagnosis of EOS. A meta-analysis of eight research enrolling neonates with documented sepsis stated that IL-8 had a global sensitivity and specificity for sepsis diagnosis of 78% and 84%, respectively [85]. However, definitive conclusions ought to no longer be drawn as research used one-of-a-kind cut-off levels and included EOS and LOS. However, the accuracy of IL-8 appears expanded when it is blended with different

biomarkers, basically CRP. In a study about enrolling preterm infants, it used to be proven that, even though IL-8 had low sensitivity (48.15%) as a marker of LOS, an aggregate with CRP multiplied sensitivity to 78.12% [86].

C-Tumor Necrosis Factor:

Tumour necrosis factor (TNF) is a potent pro-inflammatory cytokine with a principal position in initiating a cascade of activation of different cytokines and growth factors in inflammatory responses. TNF stimulates IL-6 production and is inhibited via IL-6 itself [87]. TNF degrees increase immediately at once after exposure to an infectious agent, have a peak at about 1 h, and disappear within 3 h [88]. These characteristics give an explanation for why levels to use TNF as an early marker of sepsis have failed. Generally, the dedication of cytokines a few hours after infection initiation exhibits excessive IL-6 values, whereas TNF is no longer detectable [89].

2.3. Cell Adhesion Molecules

Several cell adhesion molecules presepsin (P-SEP), cluster differentiation molecule-64 (CD64) CD11b, sCD163, soluble trigger receptor expressed on myeloid cell-1 (sTRIM1), and pentraxin3 have been tentatively used to differentiate septic neonates from healthy subjects. Only presepsin, CD14, and sTRIM1 have been used in a range of research beneficial for drawing some conclusion related to their position in this regard [90].

2.3.1. Presepsin:

Presepsin (P-SEP) is the soluble N terminal fragment of CD14, a cell surface glycoprotein expressed by means of more than a few innate immunity cells, like monocytic and neutrophils. In case of bacterial infection, interplay between CD14 and bacterial aspects such as LPBs prompts a proinflammatory pathway via toll-like receptor four (TRL-4) that leads to an internalization of the complex. During this process, CD14 is proteolyzed by using cathepsin D, a lysosomal protease, and this outcomes in the releasing of its soluble part, P-SEP, in the circulation [91]. P-SEP kinetic research have proven that blood attention of this biomarker starts to expand within 2 h after induction, peaks at 3 h, and stays expanded for up to 4–5 h [92]. From this, it was once concluded that P-SEP ought to be used for an early identification of neonatal sepsis. Two meta-analyses, such as studies carried out in neonates with each EOS and LOS, regarded to verify this assumption [93]. However, most of these studies had big problems. The position of maternal or child factors, such as GA, birth weight, type of delivery, and maternal infections in conditioning P-SEP accuracy was once no longer defined. Moreover, the interference of the physiological variants of P-SEP values in the first days of life have been now not considered. These boundaries have raised doubts about the actual position of the P-SEP marker of sepsis in neonates [94].

A latest meta-analysis such as 12 studies of preterm or term children with EOS or EOS and LOS has higher described the relevance of quite a few maternal or neonatal elements in conditioning P-SEP accuracy for neonatal sepsis diagnosis. It was once calculated that the accuracy of this marker for an early detection of neonatal sepsis used to be barely higher in cases of EOS than in cases of LOS. This is due to the fact research enrolling solely newborns with EOS confirmed greater specificity in contrast with these enrolling a combined populace of EOS and LOS (0.99; 95% CI, 0.80–1.00 vs. 0.89; 95% CI, 0.82–0.93;&p = 0.003), however no longer an appreciably specific sensitivity (0.96; 95% CI, 0.85–0.99 vs. 0.92; 95% CI, 0.85–0.96;p = 0.35). Finally, P-SEP accuracy used to be now not related with GA and the approach used for marker detection. Moreover, latest research have led to the definition of P-SEP cut-off values for wholesome term and preterm neonates in the first three days of life, favouring early identification of neonates with EOS [95]. Starting from these findings, P-SEP is nowadays regarded a promising biomarker for the prognosis of EOS. Further research are, however, wished to exactly define cut-off values for the prognosis of LOS and to display response to remedy and sepsis evolution. Finally, the achievable use of P-SEP in affiliation with different biomarkers have to be higher studied. A latest contrast has proven that the diagnostic efficacy of P-SEP used to be perfect when used in aggregate with IL-6 and CRP in contrast when the biomarker used to be used alone. The area underneath the Rock curve (AUC) for discriminating the probably infection group from the not going infection group used to be 0.97 (95% CI: 0.911–0.990) vs. 0.845 (95% CI: 0.708–0.921) [96].

2.3.2. Soluble Triggering Receptor;

The triggering receptor expressed on myeloid cells-1 promotes the launch of proinflammatory cytokines and chemokines [97,98]. Studies carried out in neonates have proven that the soluble shape of this compound (sTREM1) will increase in serum after exposure to infectious agents, that sTREM-1 levels in neonatal plasma have been related with these in adults, and that GA,

maternal age, delivery weight, type of delivery, sex, intrauterine growth restriction, and pre-labor rupture of the membranes do no longer affect sTREM1 concentrations [99].

Studies in neonates with suspected or documented sepsis have proven that the measure of this marker can differentiate septic neonates from healthful individuals. Adly et al. stated that baseline levels of this marker have been appreciably greater in septic neonates ($p< 0.001$), even though greater in preterm infants and in those with EOS [100]. Moreover, after 48 h of antibiotic treatment, sTREM1 concentrations had been notably decrease than at baseline. However, when in contrast to different sepsis markers, effects of the research have been conflicting. Compared to CRP and PCT, sTREM1 was once found to have greater sensitivity (82% vs. 45% of CRP and 55% of PCT), however decrease specificity (48% vs. 82% of CRP and 75% of PCT) [101]. On the contrary, when in contrast to IL-6, no gain of sTREM1 use used to be evidenced [102].

2.3.3. Cluster Differentiation Molecule-64:

Cluster differentiation molecule-64 (CD64) expressed from neutrophils and monocytes allows phagocytosis and intracellular killing of opsonized micro-organisms. Its expression will increase 5–10 instances the limit level 1–6 h after bacterial infection or inflammatory stimuli [103]. Moreover, its expression is no longer influenced by GA, maternal, perinatal, or postnatal factors. For this, it was once regarded a conceivable beneficial biomarker of neonatal sepsis. However, effects of scientific research have suggested conflicting effects due to the great vary of sensitivity (26–95%) and specificity (62–97%) in different individual studies [104-107]. In a meta-analysis of 17 studies consisting of 3478 neonates, the overall pooled sensitivity, specificity, effective possibility ratio, and negative possibility ratio had been 77% (95% CI 0.74–0.79), 74% (95% CI 0.72–0.75), 3.58 (95% CI: 2.85–4.49), and 0.29 (95% CI: 0.22–0.37), respectively. However, subgroup evaluation revealed greater sensitivity and specificity in term infants than these in preterm infants, and the authors concluded that facts due to this biomarker have to be dealt with caution. More accurate outcomes may be acquired by combining CD64 with other sepsis biomarkers [108].

3-Future Prospectives

Omics applied sciences have currently been used to identify markers of sepsis in neonates. The records derived in this regard are in modern times very poor, and it appears untimely to suppose that they are used in each day scientific practice. However, it looks possibly that when techniques will be standardized and greater data will be available, they will have a distinguished diagnostic place. Some examples may additionally advise what records can be obtained and how it lets in to individualize the diagnostic and therapeutic procedure much greater than is feasible with typical markers.

Recently developed molecular biology strategies such as microarrays and next-generation sequencing applied sciences have allowed to concurrently consider expression adjustments of lots of genes at the mobile degree at the onset of sepsis and at some stage in it. Using microarray, Smith et al. recognized a 52-gene network which include genes from innate and adaptive immunity that may need to distinguish neonates with bacterial infections from wholesome controls with 98% accuracy [109]. Similar findings had been pronounced via Cernada et al. [110]. Gene expression evaluation evidenced that 554 genes in general linked to cytokine secretion should discriminate VLBW neonates with sepsis from controls with a 100% sensitivity and 68% specificity.

Important data on neonatal sepsis can additionally be derived from the assessment of gene expression mediated by using epigenetic mechanisms. As microRNAs (miRNAs) can substantially have an effect on post transcriptional rules of gene expression enjoying a vital position in the improvement of immune system functions, inflammatory response, and sepsis development [111,112], the use of miRNAs as doable markers of sepsis was once considered. Initial research in this regard have proven that in patients with sepsis, serum concentrations of numerous miRNAs may need to be related with the risk of disease development, and in patients with disease, ought to assumed prognosis [113]. Studies in neonates are few, however some of them have truly evidenced that miR-16, miR-16A, nmiR96-5p, miR-141, miR-181.a, and MIR-1184 have good sized diagnostic workable for neonatal sepsis monitoring [88]. Levels of exclusive miRNAs in babies with sepsis are greater or lower than in wholesome matched children, in accordance to the role performed with the aid of the single miRNA in the immune system function. In general, overexpression of miRNA is related with improved concentrations of pro-inflammatory cytokines, and the contrary happens when a miRNA downregulates inflammatory markers [89].

Metabolomic phenotyping of septic neonates the usage of nuclear magnetic resonance imaging (NMR) and mass spectrometry can additionally be used for the prognosis of neonatal sepsis.

Volatile organic compound (VOC) evaluation on a variety of pattern sorts via different methods is a non-invasive technique to display changes of cell metabolism and intestine microbiota composition. Several studies have proven that VOC originated from the intestine are one-of-a-kind in wholesome topics than in these with certain diseases or risk conditions, and that VOC evaluation can lead to an early and accurate detection of inflammatory bowel diseases, cancer, Alzheimer's disease, and preterm birth. Recently, fecal VOC profiles of neonates have been studied with more than a various recognition techniques. The significance of an early VOC evaluation was once evidenced, as it can permit for preclinical discrimination between children growing LOS and matched controls. Berkhout et al. in contrast VOC profiles of 127 preterm kiddies with LOS to those of 127 matched healthy controls at 3, 2, and 1 day earlier than medical LOS onset [114]. Deep variations between groups at all three predefined time points have been evidenced, regardless of LOS aetiology, even though the absolute best accuracy rates have been obtained for infections due to Escherichia coli, accompanied by way of Staphylococcus aureus and Staphylococcus epidermis. Conclusions had been that VOS evaluation should have an excessive predictive rate up to three days earlier than the medical onset of LOS.

More recently, a properly carried out study has tested the conceivable of VOC as an early, non-invasive biomarker for LOS, permitting to deepen the role of the strategies used to become aware of VOCs and the aetiology of LOS in conditioning the discriminatory capability of the test [115]. Data gathered in 121 LOS preterm children and 121 matched controls have indicated that the use of gas chromatography-ion flight spectrometry (GC-IMS) for feces evaluation presents higher effects than gasoline chromatography coupled to time-of-flight mass spectrometry (GC-TOF-MS). With GC-IMS, variations between LOS cases and healthy children can be detected already three days earlier than LOS onset, whereas GC-TOF-MS evaluation can reveal variations solely extensively nearer to disease development. Moreover, identification of babies at hazard of LOS occurs before when gram-negative rods are the disorder agents. Finally, variations in accordance to single agents had been identified. In cases due to Staphylococcus aureus, VOCs had been discriminative from controls at three days earlier than LOS. On the contrary, when coagulase negative strains have been the infecting agents, discrimination was once possible only when all time factors had been combined. Despite these fascinating results, it looks obligatory that earlier than VOC evaluation can enter in routine clinical practices, in addition studies are needed. The techniques used to become aware of VOCs are expensive, time-consuming, and require relatively skilled operators. Only simplified checks can have a future in neonatal sepsis diagnosis. On the different hand, no facts have been amassed in time period neonates and in adolescents with EOS, and no statistics is reachable concerning the role of prophylactic antibiotic therapy, regularly given in neonates earlier than LOS development in conditioning VOC evaluation results.

II. Conclusion

Blood cultures, however regarded the gold famous for neonatal sepsis prognosis, have several limitations, regularly the very low sensitivity and the long TAT, that keep away from its movements use as sole marker of neonatal sepsis in clinical exercise. to conquer this trouble, inside the final thirty years, limitless efforts to discover greater reliable choices were made. alas, not one of the markers that have been proposed fulfils all of the standards for becoming a first-rate marker. White blood cell depend and differential depend have very low accuracy in figuring out neonates with sepsis and allow, at maximum, to rule out the sickness. Acute phase reactants, which includes CRP and PCT, are the most used markers. each have numerous boundaries. They, particularly CRP, have non-best kinetic traits and are strongly motivated through pre-, peri-, and postnatal factors, making it very tough to set up particular cut-off levels. a few gain may also moreover possibly be supplied via SAA, despite the fact that for this marker, dependable and definitive records on the feature of a few pre- and postnatal elements in influencing serum degrees are lacking and cut-off stages are no longer definitively hooked up. similar conclusions can be drawn when the outcomes of research concerning cytokine use are taken into consideration. The discover about of the immune device response to infections has caused the identity of a few markers, which include mobile-adhesion molecules, possibly beneficial in the identification of neonates with sepsis. Presepsin is the one greater usually studied, but for this biomarker also, accessible records are not adequate to suggest its activities use in clinical practice. The utility of omics implemented sciences to the evaluation and treatment of neonatal sepsis ought to lead to the identity of novel biomarkers. analyzing sepsis during the transcriptional and metabolic response at extraordinary instances can permit us to understand interactions between genes and biomolecules, and to select out now not totally younger human beings at chance or with defined ailment, but these with the most tough direction. A custom designed intervention could be viable. sadly, these implemented sciences are nevertheless in development and several years will must skip in advance than they may be robotically used in the NICU.

In end, in spite of immoderate research, the evaluation of neonatal sepsis and the conduct of antibiotic remedy cannot be at cutting-edge decided on the muse of a unmarriedee biomarker. Given the significance of the problem and the need to limit the abuse of antibiotics, similarly studies are urgently required. but, as a substitute of attempting to find new biomarkers, it appears much less complicated and additional effective to test combos of or extra of the nowadays on hand biomarkers. Combining effects of cytokine and everyday inflammatory markers self-discipline may additionally moreover be a feasible answer, especially whilst serial measurements are accomplished. moreover, studies primarily based totally on omics implemented sciences should be strongly boosted. but, at the same time as prepared for brand spanking new facts, using the scientific rankings prepared with the resource of some clinical establishments ought to be suggested. primarily based on maternal risk factors and baby clinical signs, sepsis chance can be calculated and a significant reduction of antibiotic consumption may be obtained.

Conflict of Interest

All authors declare no conflicts of interest.

Author Contribution

Authors have equally participated and shared every item of the work.

References

[1]-Weston, Emily J., et al. "The burden of invasive early-onset neonatal sepsis in the United States, 2005–2008." The Pediatric infectious disease journal 30.11 (2011): 937.

[2]-Oza, Shefali, et al. "Neonatal cause-of-death estimates for the early and late neonatal periods for 194 countries: 2000–2013." Bulletin of the World Health Organization 93 (2014): 19-28.

[3]-Stoll, Barbara J., et al. "Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection." Jama 292.19 (2004): 2357-2365.

[4]-Wynn, James L. "Defining neonatal sepsis." Current opinion in pediatrics 28.2 (2016): 135.

[5]-Boghossian, Nansi S., et al. "Late-onset sepsis in very low birth weight infants from singleton and multiple-gestation births." The Journal of pediatrics 162.6 (2013): 1120-1124.

[6]-Stoll, Barbara J., et al. "Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues." Pediatrics 127.5 (2011): 817-826.

[7]-Mukhopadhyay, Sagori, Eric C. Eichenwald, and Karen M. Puopolo. "Neonatal early-onset sepsis evaluations among well-appearing infants: projected impact of changes in CDC GBS guidelines." Journal of perinatology 33.3 (2013): 198-205.

[8]-Kuzniewicz, Michael W., et al. "Development and implementation of an early-onset sepsis calculator to guide antibiotic management in late preterm and term neonates." Joint Commission journal on quality and patient safety 42.5 (2016): 232-239.

[9]-Amare, Desalegne, Masresha Mela, and Getenet Dessie. "Unfinished agenda of the neonates in developing countries: magnitude of neonatal sepsis: systematic review and meta-analysis." Heliyon 5.9 (2019).

[10]-Stoll, Barbara J., et al. "Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network." Pediatrics 110.2 (2002): 285-291.

[11]-Tsai, Ming-Horng, et al. "Incidence, clinical characteristics and risk factors for adverse outcome in neonates with late-onset sepsis." The Pediatric infectious disease journal 33.1 (2014): e7-e13.

[12]-Singer, Mervyn, et al. "The third international consensus definitions for sepsis and septic shock (Sepsis-3)." Jama 315.8 (2016): 801-810.

[13]-Hofer, Nora, et al. "Performance of the definitions of the systemic inflammatory response syndrome and sepsis in neonates." Journal of perinatal medicine 40.5 (2012): 587-590.

[14]-Wynn, James L., et al. "Time for a neonatal–specific consensus definition for sepsis." Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 15.6 (2014): 523.

[15]-PrabhuDas, Mercy, et al. "Challenges in infant immunity: implications for responses to infection and vaccines." Nature immunology 12.3 (2011): 189-194.

[16]-Steinberger, Eva, Nora Hofer, and Bernhard Resch. "Cord blood procalcitonin and Interleukin-6 are highly sensitive and specific in the prediction of early-onset sepsis in preterm infants." Scandinavian journal of clinical and laboratory investigation 74.5 (2014): 432-436.

[17]-Chiesa, Claudio, et al. "C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness severity, risk status, antenatal and perinatal complications, and infection." Clinical chemistry 49.1 (2003): 60-68.

[18]-Morris, Rachel, et al. "Comparison of the management recommendations of the Kaiser Permanente neonatal early-onset sepsis risk calculator (SRC) with NICE guideline CG149 in infants≥ 34 weeks' gestation who developed early-onset sepsis." Archives of Disease in Childhood-Fetal and Neonatal Edition 105.6 (2020): 581-586.

[19]-Hershkovich–Shporen, Calanit, et al. "Centers for disease control and prevention guidelines identified more neonates at risk of early-onset sepsis than the Kaiser-Permanente calculator." Acta Paediatrica 111.4 (2022): 767-771.

[20]-Bakhuizen, Sabine E., et al. "Meta-analysis shows that infants who have suffered neonatal sepsis face an increased risk of mortality and severe complications." Acta Paediatrica 103.12 (2014): 1211-1218.

[21]-Porta, Alessandro, et al. "Off-label antibiotic use in children in three European countries." European journal of clinical pharmacology 66 (2010): 919-927.

[22]-Chakkarapani, Aravanan Anbu, and Alison Bedford Russell. "Antibiotic stewardship in the neonatal intensive care unit." Paediatrics and Child Health 29.6 (2019): 269-273.

[23]-Lee, Kelley R., Bindiya Bagga, and Sandra R. Arnold. "Reduction of broad-spectrum antimicrobial use in a tertiary children's hospital post antimicrobial stewardship program guideline implementation." Pediatric critical care medicine 17.3 (2016): 187-193.

[24]-Beerlage-de Jong, Nienke, et al. "Technology to support integrated antimicrobial stewardship programs: a user centered and stakeholder driven development approach." Infectious disease reports 9.1 (2017): 6829.

[25]-Ho, Timmy, et al. "Adherence of newborn-specific antibiotic stewardship programs to CDC recommendations." Pediatrics 142.6 (2018).

[26]-Schulman, Joseph, et al. "Neonatal intensive care unit antibiotic use." Pediatrics 135.5 (2015): 826-833.

[27]-Cotten, Charles M. "Adverse consequences of neonatal antibiotic exposure." Current opinion in pediatrics 28.2 (2016): 141-149.

[28]-Sharma, Deepak, et al. "Biomarkers for diagnosis of neonatal sepsis: a literature review." The Journal of Maternal-Fetal & Neonatal Medicine 31.12 (2018): 1646-1659.

[29]-Kellogg, James A., et al. "Frequency of low level bacteremia in infants from birth to two months of age." The Pediatric infectious disease journal 16.4 (1997): 381-385.

[30]-Woodford, Emily C., et al. "Neonatal blood culture inoculant volume: feasibility and challenges." Pediatric research 90.5 (2021): 1086-1092.

[31]-Yager, Paul, et al. "Microfluidic diagnostic technologies for global public health." Nature 442.7101 (2006): 412-418.

[32]-Pammi, Mohan, et al. "Molecular assays in the diagnosis of neonatal sepsis: a systematic review and meta-analysis." Pediatrics 128.4 (2011): e973-e985.

[33]-Da Silva, Orlando, Arne Ohlsson, and Cynthia Kenyon. "Accuracy of leukocyte indices and C-reactive protein for diagnosis of neonatal sepsis: a critical review." The Pediatric infectious disease journal 14.5 (1995): 362-366.

[34]-GREENBERG, DAVID N., and MAJOR BRADLEY A. YODER. "Changes in the differential white blood cell count in screening for group B streptococcal sepsis." The Pediatric infectious disease journal 9.12 (1990): 886-889.

[35]-Escobar, Gabriel J., et al. "Early discontinuation of antibiotic treatment in newborn admitted to rule out sepsis: a decision rule." The Pediatric infectious disease journal 13.10 (1994): 860-866.

[36]-Escobar, Gabriel J., et al. "Neonatal sepsis workups in infants≥ 2000 grams at birth: a population-based study." Pediatrics 106.2 (2000): 256-263.

[37]-Newman, Thomas B., et al. "Interpreting complete blood counts soon after birth in newborns at risk for sepsis." Pediatrics 126.5 (2010): 903-909.

[38]-Hornik, Christoph P., et al. "Use of the complete blood cell count in early-onset neonatal sepsis." The Pediatric infectious disease journal 31.8 (2012): 799.

[39]-Murphy, Kara, and Joel Weiner. "Use of leukocyte counts in evaluation of early-onset neonatal sepsis." The Pediatric infectious disease journal 31.1 (2012): 16-19.

[40]-Jethani, Sumit, Namita Bhutani, and Abhishek Yadav. "Diagnostic utility of combined immature and total neutrophil counts along with C-reactive protein in early detection of neonatal sepsis: A cross-sectional study." Annals of Medicine and Surgery 77 (2022): 103589.

[41]-van der Meer, Wim, et al. "Does the band cell survive the 21st century?." European journal of haematology 76.3 (2006): 251-254.

[42]-Black, Steven, Irving Kushner, and David Samols. "C-reactive protein." Journal of Biological Chemistry 279.47 (2004): 48487-48490.

[43]-Sharma, Anita, et al. "Evaluation of sepsis screen for diagnosis of neonatal septicemia." The Indian Journal of Pediatrics 60 (1993): 559-563.

[44]-Perrone, Serafina, et al. "C reactive protein in healthy term newborns during the first 48 hours of life." Archives of Disease in Childhood-Fetal and Neonatal Edition 103.2 (2018): F163-F166.

[45]-Simonsen, Kari A., et al. "Early-onset neonatal sepsis." Clinical microbiology reviews 27.1 (2014): 21-47.

[46]-Bomela, Hlwelekazi N., et al. "Use of C-reactive protein to guide duration of empiric antibiotic therapy in suspected early neonatal sepsis." The Pediatric infectious disease journal 19.6 (2000): 531-535.

[47]-Hofer, Nora, et al. "An update on the use of C-reactive protein in early-onset neonatal sepsis: current insights and new tasks." Neonatology 102.1 (2012): 25-36.

[48]-Whicher, John, Jacques Bienvenu, and Guillaume Monneret. "Procalcitonin as an acute phase marker." Annals of clinical biochemistry 38.5 (2001): 483-493.

[49]-Christ-Carin, M. "Procalcitonin in bacterial infections-hype, hope, more or less?." Swiss medical weekly 135.3132 (2005): 451-451.

[50]-Esposito, Susanna, et al. "Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia." Respiratory medicine 105.12 (2011): 1939-1945.

[51]-Oberhoffer, Mathias, et al. "Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro." Journal of laboratory and Clinical Medicine 134.1 (1999): 49-55.

[52]-Chiesa, Claudio, et al. "Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates." Clinical Infectious Diseases 26.3 (1998): 664-672.

[53]-Chiesa, Claudio, et al. "C reactive protein and procalcitonin: reference intervals for preterm and term newborns during the early neonatal period." Clinica Chimica Acta 412.11-12 (2011): 1053-1059.

[54]-Turner, Dan, et al. "Procalcitonin in preterm infants during the first few days of life: introducing an age related nomogram." Archives of Disease in Childhood-Fetal and Neonatal Edition 91.4 (2006): F283-F286.

[55]-Lapillonne, Alexandre, et al. "Lack of specificity of procalcitonin for sepsis diagnosis in premature infants." The Lancet 351.9110 (1998): 1211-1212.

[56]-Monneret, Guillaume, et al. "Increased Serum Procalcitonin Levels Are Not Specific to Sepsis in Neonates [with Reply]." Clinical infectious diseases (1998): 1559-1561.

[57]-Vazzalwar, Ramesh, et al. "Procalcitonin as a screening test for late-onset sepsis in preterm very low birth weight infants." Journal of perinatology 25.6 (2005): 397-402.

[58]-Eschborn, Samantha, and Joern-Hendrik Weitkamp. "Procalcitonin versus C-reactive protein: review of kinetics and performance for diagnosis of neonatal sepsis." Journal of Perinatology 39.7 (2019): 893-903.

[59]-Reyes, C. Santana, et al. "Role of cytokines (interleukin-1β, 6, 8, tumour necrosis factor-α, and soluble receptor of interleukin-2) and C-reactive protein in the diagnosis of neonatal sepsis." Acta Paediatrica 92.2 (2003): 221-227.

[60]-Sack Jr, George H. "Serum amyloid A–a review." Molecular medicine 24.1 (2018): 46.

[61]-Lannergård, Anders, et al. "Serum amyloid A (SAA) protein and high-sensitivity C-reactive protein (hsCRP) in healthy newborn infants and healthy young through elderly adults." Acta Paediatrica 94.9 (2005): 1198-1202.

[62]-Cetinkaya, M., et al. "Comparison of serum amyloid A concentrations with those of C-reactive protein and procalcitonin in diagnosis and follow-up of neonatal sepsis in premature infants." Journal of Perinatology 29.3 (2009): 225-231.

[63]-Bengnér, Johannes, et al. "Serum amyloid A–A prime candidate for identification of neonatal sepsis." Clinical Immunology 229 (2021): 108787.

[64]-Bourika, Vasiliki, et al. "Clinical value of serum amyloid-A protein, high-density lipoprotein cholesterol and apolipoprotein-A1 in the diagnosis and follow-up of neonatal sepsis." The Pediatric Infectious Disease Journal 39.8 (2020): 749-755.

[65]-Bengnér, Johannes, et al. "Serum amyloid A–A prime candidate for identification of neonatal sepsis." Clinical Immunology 229 (2021): 108787.

[66]-Fendler, Wojciech M., and Andrzej J. Piotrowski. "Procalcitonin in the early diagnosis of nosocomial sepsis in preterm neonates." Journal of paediatrics and child health 44.3 (2008): 114-118.

[67]-Yuan, Haining, et al. "Diagnosis value of the serum amyloid A test in neonatal sepsis: a meta-analysis." BioMed research international 2013 (2013).

[68]-Zudaire, Enrique, Sergio Portal-Nunez, and Frank Cuttitta. "The central role of noradrenalin in host defense." Journal of leukocyte biology 80.2 (2006): 237-244.

[69]-Fahmey, Sameh Samir, et al. "Diagnostic and prognostic value of proadrenomedullin in neonatal sepsis." Korean journal of pediatrics 61.5 (2018): 156.

[70]-Kannan, Raja, et al. "Diagnostic and prognostic validity of Proadrenomedullin among neonates with Sepsis in tertiary care hospitals of southern India." International Journal of Pediatrics 2018 (2018).

[71]-Cetin, Orkun, et al. "Serial ultrasonographic examination of the fetal thymus in the prediction of early neonatal sepsis in preterm premature rupture of membranes." Gynecologic and Obstetric Investigation 78.3 (2014): 201-207.

[72]-Wu, Tai-Wei, et al. "The utility of serum hepcidin as a biomarker for late-onset neonatal sepsis." The Journal of pediatrics 162.1 (2013): 67-71.

[73]-Rao, Lubei, et al. "Progranulin as a novel biomarker in diagnosis of early-onset neonatal sepsis." Cytokine 128 (2020): 155000.

[74]-Badr, Hassan S., Fady M. El-Gendy, and Mohamed A. Helwa. "Serum stromal-derived-factor-1 (CXCL12) and its alpha chemokine receptor (CXCR4) as biomarkers in neonatal sepsis." The Journal of Maternal-Fetal & Neonatal Medicine 31.16 (2018): 2209-2215.

[75]-Zonda, Gabriela Ildiko, et al. "Endocan-a potential diagnostic marker for early onset sepsis in neonates." The Journal of Infection in Developing Countries 13.04 (2019): 311-317.

[76]-Fahmey, S. S., and N. Mostafa. "Pentraxin 3 as a novel diagnostic marker in neonatal sepsis." Journal of neonatal-perinatal medicine 12.4 (2019): 437-442.

[77]-Wu, Lijie, et al. "Diagnostic Value of Inflammatory Markers and Cytokines in Neonatal Sepsis." Evidence-Based Complementary and Alternative Medicine 2022 (2022).

[78]-Liu, Guozhen, et al. "Point-of-care detection of cytokines in cytokine storm management and beyond: Significance and challenges." View 2.4 (2021): 20210003.

[79]-Küster, Helmut, et al. "Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation." The Lancet 352.9136 (1998): 1271-1277.

[80]-Ng, Pak C., and Hugh S. Lam. "Biomarkers for late-onset neonatal sepsis: cytokines and beyond." Clinics in perinatology 37.3 (2010): 599-610.

[81]-Eichberger, Julia, and Bernhard Resch. "Reliability of interleukin-6 alone and in combination for diagnosis of early onset neonatal sepsis: systematic review." Frontiers in Pediatrics 10 (2022): 840778.

[82]-Raynor, Laura L., et al. "Cytokine screening identifies NICU patients with Gram-negative bacteremia." Pediatric research 71.3 (2012): 261-266.

[83]-Zhou, Min, et al. "Interleukin-8 for diagnosis of neonatal sepsis: a meta-analysis." PloS one 10.5 (2015): e0127170.

[84]-Dillenseger, Laurence, et al. "Early inflammatory markers for the diagnosis of late-onset sepsis in neonates: the nosodiag study." Frontiers in pediatrics 6 (2018): 346.

[85]-Schindler, Ralf, et al. "Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF." (1990): 40-47.

[86]-Formosa, Amanda, Paul Turgeon, and Claudia C. Dos Santos. "Role of miRNA dysregulation in sepsis." Molecular Medicine 28.1 (2022): 99.

[87]-Jouza, Martin, et al. "MicroRNA as an early biomarker of neonatal sepsis." Frontiers in pediatrics 10 (2022): 854324.

[88]-Gude, Sai Sravya, et al. "Biomarkers of neonatal sepsis: From being mere numbers to becoming guiding diagnostics." Cureus 14.3 (2022).

[89]-Chenevier-Gobeaux, Camille, et al. "Presepsin (sCD14-ST), an innate immune response marker in sepsis." Clinica chimica acta 450 (2015): 97-103.

[90]-Schulman, Joseph, et al. "Newborn antibiotic exposures and association with proven bloodstream infection." Pediatrics 144.5 (2019).

[91]-Parri, Niccolò, et al. "Accuracy of presepsin in neonatal sepsis: Systematic review and meta-analysis." Expert Review of Anti-Infective Therapy 17.4 (2019): 223-232.

[92]-Ergor, Serap Nur, et al. "Reference ranges of presepsin (soluble CD14 subtype) in term and preterm neonates without infection, in relation to gestational and postnatal age, in the first 28 days of life." Clinical Biochemistry 77 (2020): 7-13.

[93]-Pugni, Lorenza, et al. "Presepsin (soluble CD14 subtype): reference ranges of a new sepsis marker in term and preterm neonates." PloS one 10.12 (2015): e0146020.

[94]-Poggi, Chiara, et al. "Presepsin for the detection of late-onset sepsis in preterm newborns." Pediatrics 135.1 (2015): 68-75.

[95]-Mussap, Michele, et al. "Soluble CD14 subtype (sCD14-ST) presepsin in premature and full term critically ill newborns with sepsis and SIRS." Clinica Chimica Acta 451 (2015): 65-70.

[96]-Bouchon, Axel, et al. "TREM-1 amplifies inflammation and is a crucial mediator of septic shock." Nature 410.6832 (2001): 1103-1107.

[97]-Garofoli, F., et al. "Preterm newborns are provided with triggering receptor expressed on myeloid cells-1." International Journal of Immunopathology and Pharmacology 23.4 (2010): 1297-1301.

[98]-Adly, Amira AM, et al. "Circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as diagnostic and prognostic marker in neonatal sepsis." Cytokine 65.2 (2014): 184-191.

[99]-Stein, Michal, et al. "The accuracy of C-reactive protein, procalcitonin, and s-TREM-1 in the prediction of serious bacterial infection in neonates." Clinical pediatrics 54.5 (2015): 439-444.

[100]-Sarafidis, Kosmas, et al. "Diagnostic utility of elevated serum soluble triggering receptor expressed on myeloid cells (sTREM)-1 in infected neonates." Intensive care medicine 36 (2010): 864-868.

[101]-Lv, Bokun, et al. "Tumor necrosis factor-α as a diagnostic marker for neonatal sepsis: a meta-analysis." The Scientific World Journal 2014 (2014).

[102]-Layseca-Espinosa, Esther, et al. "Expression of CD64 as a potential marker of neonatal sepsis." Pediatric allergy and immunology 13.5 (2002): 319-327.

[103]-Ng, Pak C., et al. "Neutrophil CD64 expression: a sensitive diagnostic marker for late-onset nosocomial infection in very low birthweight infants." Pediatric research 51.3 (2002): 296-303.

[104]-Ng, Pak C., et al. "Neutrophil CD64 is a sensitive diagnostic marker for early-onset neonatal infection." Pediatric research 56.5 (2004): 796-803.

[105]-Bhandari, Vineet, et al. "Hematologic profile of sepsis in neonates: neutrophil CD64 as a diagnostic marker." Pediatrics 121.1 (2008): 129-134.

[106]-Elawady, Sanaa, et al. "Neutrophil CD64 as a diagnostic marker of sepsis in neonates." Journal of Investigative Medicine 62.3 (2014): 644-649.

[107]-Smith, Claire L., et al. "Identification of a human neonatal immune-metabolic network associated with bacterial infection." Nature communications 5.1 (2014): 4649.

[108]-Cernada, María, et al. "Genome-wide expression profiles in very low birth weight infants with neonatal sepsis." Pediatrics 133.5 (2014): e1203-e1211.

[109]-Fatmi, Ahlam, et al. "Clinical and immunological aspects of microRNAs in neonatal sepsis." Biomedicine & Pharmacotherapy 145 (2022): 112444.

[110]-Bushati, Natascha, and Stephen M. Cohen. "microRNA functions." Annu. Rev. Cell Dev. Biol. 23 (2007): 175-205.

[111]-Antonakos, Nikolaos, et al. "Modes of action and diagnostic value of miRNAs in sepsis." Frontiers in Immunology (2022): 4172.

[112]-Berkhout, Daniel JC, et al. "Late-onset sepsis in preterm infants can be detected preclinically by fecal volatile organic compound analysis: a prospective, multicenter cohort study." Clinical Infectious Diseases 68.1 (2019): 70-77.

[113]-Frerichs, Nina M., et al. "Fecal Volatile Metabolomics Predict Gram-Negative Late-Onset Sepsis in Preterm Infants: A Nationwide Case-Control Study." Microorganisms 11.3 (2023): 572.

[114]-Berkhout, Daniel JC, et al. "Late-onset sepsis in preterm infants can be detected preclinically by fecal volatile organic compound analysis: a prospective, multicenter cohort study." Clinical Infectious Diseases 68.1 (2019): 70-77.

[115]-Frerichs, Nina M., et al. "Fecal Volatile Metabolomics Predict Gram-Negative Late-Onset Sepsis in Preterm Infants: A Nationwide Case-Control Study." Microorganisms 11.3 (2023): 572.